“The present condition has exposed some structural weaknesses from the EU’s medicines supply chain plus a significant dependence on non-EU nations for active pharmaceutical ingredients,” Kyriakides reported. She suggested that offer chain concerns be tackled in an EU pharmaceutical tactic expected to become introduced by the top in the 12 mon